Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.3 USD | +2.32% | +2.91% | -23.74% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company sustains low margins.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 92.17 times its estimated earnings per share for the ongoing year.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-23.74% | 882M | C- | ||
+6.84% | 27.04B | B+ | ||
-40.08% | 2.82B | B- | ||
-19.95% | 2.42B | C+ | ||
+16.30% | 2.32B | B | ||
+7.28% | 2.22B | - | A- | |
+16.67% | 1.8B | B | ||
-13.56% | 1.8B | - | ||
+18.92% | 1.25B | B | ||
+20.00% | 1.21B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FIGS Stock
- Ratings FIGS, Inc.